Want to join the conversation?
$PFE said Xeljanz has been prescribed to more than 50,000 patients worldwide. 2Q16 revenue was $217MM, representing 70% operational growth versus 2Q15. More than 3.5MM patients already have been prescribed Eliquis, and it is now the number one prescribed oral anticoagulant amongst cardiologists in the US, Japan and several European countries.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.